Founded in 2017, the company has been pioneering alternative methods of protein production that do not rely on conventional agriculture and lays claim to being the first in the world to receive a positive EFSA scientific opinion for a novel food ingredient produced through gas fermentation. The fermentation method enables cost-effective production at scale, making significant volumes of protein accessible to consumers at affordable prices—an issue particularly relevant given the recent surge in whey protein prices.
“This is a defining moment for Solar Foods, as the positive opinion enables us to advance our offtake negotiations, financing and preparations for the final investment decision for Factory 02,” said Rami Jokela, CEO of Solar Foods. “After years of proving the technology, product and production process, our focus is increasingly on commercial execution and scaling the business.”
Factory 02 (FO2), Solar Foods’ planned commercial-scale production facility, is designed to manufacture Solein in significantly larger volumes. The company is currently advancing multi-year binding offtake negotiations with major consumer packaged goods (CPG) companies, food ingredient distributors and health and performance brands to secure future production volumes.
While the EFSA opinion outlines the proposed categories of use for Solein, the final authorization decision now rests with the European Commission.
Solar Foods says that it expects the approval process to take between seven and nine months, based on recent novel food authorization timelines, after which the company will begin to commercialize Solein across the EU within the approved conditions of use.

Solein’s current regulatory status
In October 2021, Solar Foods submitted its EU Novel Food application for Solein, delivered as a yellow powder containing approximately 80% protein, all nine essential amino acids, alongside iron and B vitamins. An extensive EFSA safety assessment followed.
“EFSA is considered the gold standard for food safety assessments globally,” Jokela said during a “Go-to-Market Update” webinar held on Nov. 9, in which he outlined the company’s European commercialization strategy following the positive EFSA opinion.
“Its scientific assessment is one of the most extensive and thorough food safety reviews. This positive opinion therefore provides a strong reference point for other markets, particularly those without an equivalent novel food assessment framework.”
Solar Foods also secured novel food approval for Solein in Singapore in September 2022, achieved a self-GRAS safety conclusion in the United States in 2024 and has submitted a GRAS notification to the U.S. Food and Drug Administration (FDA) for further review.
“We began the application process in 2021, so this has been a long journey,” Jokela said. “EFSA has conducted an extensive assessment of our manufacturing process and consumer safety, supported by detailed information and scientific evidence. While it has taken time, we are delighted to have achieved this positive opinion.”
Protein made from air using gas fermentation
Solein is produced through a microbial cultivation process which uses a naturally occurring, single-cell microorganism that grows by consuming gases and dissolved nutrients rather than conventional agricultural feedstocks.
Inside a specialized bioreactor, the microorganism receives carbon dioxide as a carbon source, hydrogen as an energy source, and oxygen and essential nutrients needed for growth. Renewable electricity powers the production process, including the generation of hydrogen through water electrolysis.
As the microorganism metabolizes these inputs, it converts them into cellular biomass, which Solar Foods harvests and processes into a dried, protein-rich ingredient.
“Gas fermentation enables food to be produced at scale and more cost-effectively than other fermentation technologies, potentially allowing significant volumes of protein to reach consumers at affordable prices,” Jokela said.
He added that the mounting pressure on global food systems is strengthening the case for alternative protein production and more resilient food systems.
“Looking at the bigger picture, the United Nations estimates that food production needs to increase by 60% by 2050, while climate change, water scarcity and soil degradation could reduce production capacity by 25%,” Jokela noted. “Around 43% of land is already used for agriculture, leaving limited scope for expansion. These challenges underline the importance of alternative protein production and food security.”
Solar Foods is also exploring the potential of Solein in space. The company sees space as the ultimate test of its production technology, as Solein can be manufactured in environments where conventional agriculture is impossible.
This involves developing a small-scale prototype with European space technology company OHB, under a project funded by the European Space Agency (ESA). The initial development phase is designed to test the technology on Earth before potentially sending a flight model to the International Space Station.

Opportunities in the protein market
Ilkka Saura, CFO and deputy CEO at Solar Foods, noted the significant growth opportunities in the global protein market due to changing consumer preferences, rising input costs and increasing demand for alternative protein sources.
“Animal-based proteins, particularly whey protein concentrate and isolate, have experienced unprecedented price volatility,” he said. “Food manufacturers are increasingly looking at alternative formulations to manage high input costs.”
Saura noted that the protein market shows great growth opportunities across both Europe and the United States.
“The total addressable market for Solein in the European Union is expected to reach €7 billion by 2030, making it the second-largest protein market globally,” he said. “Combined with the US, the total addressable market could reach approximately €18 billion by 2030, representing a compound annual growth rate of 8% between 2025 and 2030.”
Key target markets for Solein include protein bars, ready-to-drink beverages and protein ice cream, with further applications across baked goods and ready-to-mix shakes.
“By 2030, an estimated 70 million adults across Europe and the US will be using GLP-1 treatments,” Saura said. “This could create an additional 250 kilotonnes of annual protein demand, particularly benefiting categories such as yogurt and yogurt drinks, meat snacks and nutrition bars.”
Heli Anttila, vice president of product research and development at Fazer, the Finnish food group and strategic Solar Foods partner, said the positive EFSA opinion marks an important milestone in bringing Solein-based products to European consumers.
“At Fazer, our mission is to create food with a purpose while operating within planetary boundaries,” he said. “Familiar product formats are important. Integrating Solein into products consumers already know makes it easier to try and incorporate into everyday consumption.”
“Consumer feedback following tasting has been excellent, with strong interest in product availability beyond the initial curiosity around the concept of food made from thin air,” he added.




